If You're a Long-Term Growth Investor, This Is the Sector to Be Focusing On, and It Has Nothing to Do With Artificial Intelligence

The article highlights a major regulatory milestone: the U.S. has rescheduled FDA-approved marijuana products from Schedule I to Schedule III, potentially paving the way for broader reform. It cites Fortune Business Insights estimates that the global cannabis market could grow from just under $138 billion this year to more than $1.4 trillion by 2034, implying a CAGR above 34%. The piece is constructive on cannabis as a long-term growth theme, but it also stresses elevated risk and points readers toward other preferred stocks over Tilray Brands.

Analysis

The market is underestimating how much of the upside from U.S. cannabis reform is already in the signal, not the cash flows. Rescheduling lowers regulatory friction and improves the financing narrative, but it does not fix the sector’s core problem: structurally poor unit economics, heavy dilution, and weak access to U.S. plant-touching capital. That means the first-order trade is likely a sentiment beta spike, while the second-order winners are operators with enough balance-sheet flexibility to survive a 12-24 month transition period.

The more interesting implication is relative rather than absolute. If rescheduling unlocks banking, tax, and institutional ownership optionality over time, Canadian names like TLRY may get the biggest multiple re-rating because they are the most crowded “optionality” proxies, but the fundamental capture of economic value should still accrue to U.S. multi-state operators with real store-level scale and pricing power. The market tends to overpay for headline reform and underprice the lag between policy change and P&L conversion; that gap creates a setup where event-driven upside can reverse quickly if legislative momentum stalls or if the FDA/DEA process narrows the practical benefits.

Contrarian read: the article’s long-duration market-size framing may be directionally right but tactically misleading. A trillion-dollar end-state assumes broad legalization and normalized access, yet the near-term risk is that rescheduling becomes a ceiling, not a bridge—good enough to compress risk premia, not good enough to generate EBITDA inflection. In that scenario, the best risk/reward is not chasing the most promotional name, but owning the more credible operating leverage while fading the highest-burn equity with the weakest path to self-funding.

Key Decisions for Investors

• Short TLRY vs long a basket of higher-quality U.S. MSOs on a 3-6 month horizon; TLRY is the cleanest sentiment proxy, but its cash-burn and dilution risk make it vulnerable if the reform story cools.
• Add opportunistically to MSO exposure on post-rally pullbacks rather than strength, using a 6-12 month window; focus on names with better liquidity and store-level EBITDA leverage, as they should outperform if banking/tax normalization advances.
• Use call spreads, not outright longs, for event-driven exposure to cannabis reform over the next 1-3 months; implied volatility should be elevated, so capped upside structures improve risk/reward.
• Avoid chasing the broad “legalization next” basket; instead, prefer a pair trade long U.S.-operating capacity / short speculative Canadian hemp or cash-burning names, because policy optionality should accrue unevenly.
• If TLRY squeezes on headlines, trim into strength rather than average up; the stock’s upside is mostly narrative-driven until there is clear evidence of U.S. revenue conversion or improved free cash flow.